CANbridge Pharmaceuticals Inc. operates as a rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies. The firm's pipeline and products include rare oncology, rare diseases, gene theraphy, Huntercase, Nerlynx, and Caphosol. It operates through the following geographical segment: Mainland China, Taiwan, and Hong Kong. The company was founded by James Xue in 2012 and is headquartered in Beijing, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company